Chronic hepatitis C (CHC) is a significant global health burden, and direct-acting antiviral agents (DAAs) have transformed its treatment landscape, offering high cure rates and improved outcomes. Among these agents, sofosbuvir and daclatasvir have shown exceptional efficacy and safety in eradicating the hepatitis C virus (HCV), with shorter treatment durations and fewer adverse effects. Emerging evidence suggests that DAAs may also influence metabolic parameters and health-related quality of life (HRQoL) in CHC patients, making it essential to comprehensively assess their impact. Methods: This prospective, single-center, observational study aimed to evaluate the effects of sofosbuvir and daclatasvir on lipid profile, glycemic control, and HRQoL in adult CHC patients (n=60) receiving the treatment regimen at a tertiary care hospital in Uttar Pradesh. Baseline demographic information, medical history, and laboratory data were collected. Lipid profile and glycemic control were assessed through fasting blood samples, while HRQoL was measured using the Short Form-36 (SF-36) questionnaire administered at baseline and post-treatment. Statistical analysis was performed to determine changes in the outcomes, with a p-value < 0.05 considered statistically significant. Results: Following 12 weeks of treatment, significant improvements were observed in lipid profile, with reductions in total cholesterol (p<0.05), LDL cholesterol (p<0.05), and triglycerides (p<0.05). HDL cholesterol showed a modest increase, though not statistically significant. Glycemic control also improved, with reductions in fasting blood glucose (p<0.05) and HbA1c levels (p<0.05). Quality of life significantly improved across all domains of the SF-36 questionnaire (p<0.05). Additionally, an impressive virologic response rate of 96.7% was achieved, indicating SVR12 in the majority of participants. Conclusion: Treatment with sofosbuvir and daclatasvir in CHC patients resulted in favorable changes in lipid profile, glycemic control, and quality of life. The high virologic response rate further supports the effectiveness of this DAA combination in achieving SVR12. These findings provide valuable insights for optimizing CHC management and support the use of sofosbuvir and daclatasvir in CHC treatment